Clinical Trials Logo

Stage IV Colorectal Cancer clinical trials

View clinical trials related to Stage IV Colorectal Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05631574 Recruiting - Colorectal Cancer Clinical Trials

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Start date: January 12, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

NCT ID: NCT03368963 Recruiting - Clinical trials for Gastric Adenocarcinoma

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Start date: January 30, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT02919644 Recruiting - Clinical trials for Stage IV Colorectal Cancer

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.

COREVAX-1
Start date: December 2, 2016
Phase: Phase 2
Study type: Interventional

Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer